COVID-19 is a serious acute disease caused by the novel coronavirus SARS-CoV-2, also known as 2019-nCoV. Our expert scientific team has validated an ELISA-based test for the serological evaluation of SARS-CoV-2 exposure. This test detects the anti-SARS-CoV-2 IgG antibody, which identifies individuals who have mounted a humoral immune response after viral exposure, whether or not they became symptomatic.
Our SARS-CoV-2 IgG serology test will enable employers to formulate safe & effective "Return to Work" initiatives for their workforce. Our test results will provide a simple easy to read report showing whether an individual has generated IgG antibodies to SARS-COV-2. The presence of these antibodies is highly indicative of past exposure and will be useful information for informed decision making on how to safely return employees to the workplace
FlowMetric's assay does not diagnose COVID-19 disease, nor does it document infection, or immunity to the virus. We are offering this assay for research and clinical applications, in accordance with FDA guidelines.
Additionally, FlowMetric continues to innovate in the area of SARS-CoV-2 research and is currently developing a second generation of serological testing on a flow cytometry platform, with enhanced performance characteristics, scalability and clinical endpoints.
FlowMetric’s decade of experience in immune system analysis for drug development creates the basis for our validated immune monitoring platform, supporting robust COVID-19 serology testing.